Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept

Changes in serum cartilage oligomeric matrix protein (COMP) were studied during a 6-month period from initiation of treatment of rheumatoid arthritis patients with either infliximab or etanercept, to elucidate whether the favourable results of tissue protection reported in clinical trials are corrob...

Cijeli opis

Bibliografski detalji

Izdano u:	Arthritis Res Ther
Glavni autori:	Crnkic, Meliha, Månsson, Bengt, Larsson, Lotta, Geborek, Pierre, Heinegård, Dick, Saxne, Tore
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2003
Teme:	Research Article
Online pristup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC165057/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12823852/ https://ncbi.nlm.nih.govhttps://doi.org/10.1186/ar760
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!